Harpoon Therapeutics, Inc.

Informe acción NasdaqCM:HARP

Capitalización de mercado: US$492.3m

Salud financiera de hoja de balance de Harpoon Therapeutics

Salud financiera controles de criterios 5/6

Harpoon Therapeutics tiene un patrimonio de los accionistas total de $4.5M y una deuda total de $8.8M, lo que sitúa su ratio deuda-patrimonio en 194.4%. Sus activos y pasivos totales son $47.6M y $43.0M respectivamente.

Información clave

194.4%

Ratio deuda-patrimonio

US$8.83m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$31.61m
PatrimonioUS$4.54m
Total pasivoUS$43.04m
Activos totalesUS$47.58m

Actualizaciones recientes sobre salud financiera

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($34.3M) de HARP superan a sus pasivos a corto plazo ($18.1M).

Pasivo a largo plazo: Los activos a corto plazo de HARP ($34.3M) superan a sus pasivos a largo plazo ($24.9M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: HARP tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de HARP ha crecido de 0% a 194.4% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: HARP tiene suficiente cash runway para 5 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que HARP disponga de suficiente cash runway para 11 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target